TD Asset Management
YMAB

TD Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

TD Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,753
Closed -$697K – 1426
2019
Q3 		$697K Buy
26,753
+1,300
+5% +$33.2K ﹤0.01% 1122
2019
Q2 		$582K Buy
25,453
+2,624
+11% +$60.3K ﹤0.01% 1156
2019
Q1 		$598K Buy
22,829
+4,432
+24% +$97.3K ﹤0.01% 1148
2018
Q4 		$374K Buy
18,397
+100
+0.5% +$2.3K ﹤0.01% 1278
2018
Q3 		$486K Buy
+18,297
New +$465K ﹤0.01% 1295

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TD Asset Management's YMAB Position: Q4 2019 in Review

TD Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2019, closing a stake of 26,753 shares — an estimated $697K sold.

TD Asset Management first reported a position in YMAB in Q3 2018 and held it in 5 quarters. The position peaked at $697K in Q3 2019. 81 funds tracked by Wall St. Rank hold YMAB as of Q4 2019.

  • TD Asset Management reported no remaining Y-mAbs Therapeutics position as of Q4 2019 after selling out during the quarter.
  • TD Asset Management sold 26,753 Y-mAbs Therapeutics shares in Q4 2019, an estimated $697K.
  • TD Asset Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 5 quarters.
  • TD Asset Management's Y-mAbs Therapeutics position peaked at $697K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2019.

Based on TD Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.